Literature DB >> 18466052

Biochemistry of Tau in Alzheimer's disease and related neurological disorders.

Nicolas Sergeant1, Alexis Bretteville, Malika Hamdane, Marie-Laure Caillet-Boudin, Pierre Grognet, Stephanie Bombois, David Blum, André Delacourte, Florence Pasquier, Eugeen Vanmechelen, Susanna Schraen-Maschke, Luc Buée.   

Abstract

Microtubule-associated Tau proteins belong to a family of factors that polymerize tubulin dimers and stabilize microtubules. Tau is strongly expressed in neurons, localized in the axon and is essential for neuronal plasticity and network. From the very beginning of Tau discovery, proteomics methods have been essential to the knowledge of Tau biochemistry and biology. In this review, we have summarized the main contributions of several proteomic methods in the understanding of Tau, including expression, post-translational modifications and structure, in both physiological and pathophysiological aspects. Finally, recent advances in proteomics technology are essential to develop further therapeutic targets and early predictive and discriminative diagnostic assays for Alzheimer's disease and related disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18466052     DOI: 10.1586/14789450.5.2.207

Source DB:  PubMed          Journal:  Expert Rev Proteomics        ISSN: 1478-9450            Impact factor:   3.940


  85 in total

Review 1.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

2.  Tau isoform composition influences rate and extent of filament formation.

Authors:  Qi Zhong; Erin E Congdon; Haikady N Nagaraja; Jeff Kuret
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

Review 3.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

4.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

5.  A2A adenosine receptor deletion is protective in a mouse model of Tauopathy.

Authors:  C Laurent; S Burnouf; B Ferry; V L Batalha; J E Coelho; Y Baqi; E Malik; E Mariciniak; S Parrot; A Van der Jeugd; E Faivre; V Flaten; C Ledent; R D'Hooge; N Sergeant; M Hamdane; S Humez; C E Müller; L V Lopes; L Buée; D Blum
Journal:  Mol Psychiatry       Date:  2014-12-02       Impact factor: 15.992

Review 6.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

7.  Effect of Phosphorylation and O-GlcNAcylation on Proline-Rich Domains of Tau.

Authors:  Lata Rani; Jeetain Mittal; Sairam S Mallajosyula
Journal:  J Phys Chem B       Date:  2020-03-02       Impact factor: 2.991

8.  Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated.

Authors:  Kanae Ando; Mikiko Oka; Yosuke Ohtake; Motoki Hayashishita; Sawako Shimizu; Shin-Ichi Hisanaga; Koichi M Iijima
Journal:  Biochem Biophys Res Commun       Date:  2016-08-09       Impact factor: 3.575

Review 9.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

10.  Ligand electronic properties modulate tau filament binding site density.

Authors:  Katryna Cisek; Jordan R Jensen; Nicolette S Honson; Kelsey N Schafer; Grace L Cooper; Jeff Kuret
Journal:  Biophys Chem       Date:  2012-09-11       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.